AAAbdullah Alabbasi

Abdullah Alabbasi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdullah Alabbasi has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Caregiver Misconceptions and Barriers to Palliative Care in Saudi Arabia: A Comprehensive Narrative Review

    by Muhanad Alzahrani, Abdullah Alabbasi, Faris A. Sultan, Mohammed Sayes, Rayan Marwan Mukhtar, Maha S. AlQahtani, Ziyad Alzahrani

    Background: Palliative care (PC) services have expanded in Saudi Arabia, yet caregiver misconceptions and limited service visibility may delay referral and create uncertainty about symptom management. Because families play a central role in care navigation and decision-making, caregiver's understanding influences when PC is considered. Addressing misconceptions is essential to improving care quality. Methods: A structured narrative review guided by the Scale for the Assessment of Narrative Review Articles involved a search of MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Google Scholar for literature published from January 1, 2000, to January 16, 2026, with targeted citation and gray literature updates through 2026. Search terms included “PC,” “end-of-life care,” “caregivers/families,” “awareness,” “opioids,” “communication,” “religion,” “Saudi Arabia,” and the “Gulf Cooperation Council.” Of 925 unique records screened, 279 underwent full-text assessment, and 63 met eligibility. The review synthesized 42 eligible evidence and implementation sources, with methodology and clinical tools supported by primary sources. Results: Six themes were identified: (1) Misunderstanding Purpose and Scope; (2) Fear of Opioids; (3) Cultural and Religious Dynamics; (4) Noncancer Awareness Gap; (5) System-Level Barriers; and (6) Implementation-Level Gaps. Nursing priorities included repeated caregiver assessment, clear symptom and medication education, teach-back, and coordinated transitions. Conclusion: Caregiver misunderstanding remains an important barrier to PC use in Saudi Arabia. Improvement requires nurse-led and interdisciplinary caregiver education, culturally attuned and faith-sensitive communication, earlier PC integration, coordinated transitions, and expanded home- and community-based services.

  • Open Access

    Pretreatment systemic inflammatory ratios and survival in osteosarcoma and other primary bone sarcomas: a systematic review and meta-analysis

    by Albara Dabroom, Muhanad Alzahrani, Abdullah Alabbasi, Khalid Alotaibi, Faris Sultan, Abdulrahman Alaseem, Ibrahim Alshaygy

    Background: Evidence for neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in primary bone sarcoma is dominated by osteosarcoma and has been affected by inconsistent endpoint and effect-size extraction. We re-extracted eligible estimates from the primary reports and evaluated their independent prognostic associations. Methods: MEDLINE, Embase, Web of Science, Scopus, and Cochrane CENTRAL were searched for cohort studies reporting pretreatment NLR, PLR, or LMR in primary bone sarcoma. The primary analysis required clinically multivariable-adjusted, categorical high-versus-low hazard ratios (HRs). Overall survival (OS) was analyzed separately from progression-free survival (PFS), disease-free survival (DFS), event-free survival (EFS), and disease-specific mortality. Random-effects models used restricted maximum likelihood (REML) estimation and Hartung-Knapp confidence intervals. Histology- and Newcastle-Ottawa Scale (NOS)-based subgroup analyses were prespecified when at least two studies were available. Results: Ten studies remained in the systematic review, and nine contributed at least one source-verifiable endpoint-specific adjusted estimate to quantitative synthesis. Seven NLR-OS cohorts yielded a pooled HR of 1.64 (95% CI 1.15–2.33; I² = 81.4%). The osteosarcoma-only subgroup remained significant (five cohorts; HR 1.70, 95% CI 1.03–2.81; I² = 86.6%). Excluding Huang X 2019 from the strict dataset yielded HR 1.84 (95% CI 1.44–2.36; I² = 0%); the reviewer-specified comparison against the previous eight-estimate set, retaining Yang Q 2020 only as a source-reported sensitivity input, yielded HR 1.90 (95% CI 1.47–2.45; I² = 5.9%). PLR was not associated with OS (four cohorts; HR 1.07, 95% CI 0.67–1.72; I² = 56.0%). LMR showed a non-significant protective trend (three cohorts; HR 0.70, 95% CI 0.38–1.27; I² = 0%). Conclusions: Higher pretreatment NLR is associated with poorer OS, including in the strict osteosarcoma-only analysis. The direction remained stable in every leave-one-out analysis, while the marked reduction in heterogeneity after excluding Huang X 2019 identifies one dominant statistical influence. Retrospective designs and residual heterogeneity limit clinical application. PLR and LMR findings remain inconclusive, and whether NLR-guided management improves outcomes is untested.

  • Proton Pump Inhibitor Exposure and Colonization With ESBL-Producing Enterobacterales

    by Muhanad Saleh Alzahrani, Abdullah Alabbasi, Mohammed Sayes, Rayyan Fahad H. Altemani, Faris A. Sultan, Layan Alhuthali

    Background: Colonization by ESBL-producing Enterobacterales drives antimicrobial resistance transmission. Proton pump inhibitors (PPIs) alter gastric pH and gut flora, potentially increasing colonization risk with enteric bacteria. However, evidence on the association between PPI exposure and ESBL-producing Enterobacterales colonization remains mixed. Methods: The study is a systematic review and meta-analysis according to the PRISMA 2020 criteria. We searched MEDLINE, Embase, and the Cochrane Library for observational studies assessing PPI exposure and ESBL-producing Enterobacterales colonization through December 2025. ORs were calculated using a random-effects meta-analysis model with Hartung-Knapp adjustments. Sensitivity analyses assessed the effect of using broader definitions of acid suppression exposure as well as alternative statistical models. Results: Three studies met the criteria for primary pooling of PPI exposure and ESBL colonization. Pooled analysis demonstrated a directionally increased but imprecise association (OR: 1.91, 95% CI: 0.34-10.91) with substantial heterogeneity ( I 2 =77%). Sensitivity analysis, including five studies with broader acid suppression exposure, yielded a smaller but directionally consistent estimate (OR: 1.49, 95% CI: 0.75-2.97; I 2 ≈ 70%). Sensitivity analyses were exploratory and did not overcome the imprecision and heterogeneity of the evidence base. Publication bias assessment was not performed because of the small sample size. Conclusions: Currently available data are insufficient to establish an association between PPI exposure and ESBL colonization. The wide confidence intervals and substantial heterogeneity render these findings hypothesis-generating rather than conclusive. Larger, methodologically robust prospective studies are needed before clinical or public health recommendations can be made.

  • Open Access

    Early Palliative Care in Gastrointestinal Oncology: Evidence, Implementation Models, and Ethical Considerations

    by Abdullah Alabbasi, Muhanad Alzahrani

    Background: Early palliative care is increasingly recognized as an important component of high-quality cancer care; however, the timing and extent of its integration vary across oncologic disciplines, including gastrointestinal (GI) oncology. Patients with GI malignancies frequently experience early symptom burden, complex treatment courses, and prognostic uncertainty, contributing to substantial supportive care needs over the disease trajectory. Methods: This narrative review synthesizes evidence on early palliative care in gastrointestinal oncology from randomized controlled trials, systematic reviews, GI oncology–specific clinical guidelines, and observational and health services research. The objective was to characterize patterns of evidence, implementation approaches, and ethical considerations relevant to early integration in gastrointestinal oncology. Results: Across heterogeneous study designs, early palliative care involvement is associated with improvements in quality of life, symptom control, and communication outcomes, without evidence of interference with disease-directed therapies. In GI oncology, particularly pancreatic cancer and hepatocellular carcinoma, unmet supportive care needs are consistently described. Diagnosis-anchored and needs-based referral approaches are discussed as alternatives to time-based models in settings of prognostic uncertainty. Evidence supporting home-based or hybrid palliative care models in GI oncology remains limited and context dependent. Conclusion: Overall, the literature suggests that earlier integration of palliative care may be appropriate for selected patients with gastrointestinal malignancies. Given variability in symptom burden and clinical trajectories, time-based referral models may be insufficient in some settings, whereas needs-based and diagnosis-anchored approaches may offer flexible frameworks. Ethical considerations should be interpreted in light of patient preferences, feasibility, and health system capacity, rather than framed as universal mandates.

  • Artificial intelligence in skin cancer research (2010–2024): a bibliometric analysis using the web of science database

    by Mohammed Naif Alsubhi, Faris Alaa Sultan, Abdullah Ahmed Alabbasi, Muhanad Saleh Alzahrani, Maha S Alqahtani, Muhannad Q. Alqirnas

  • Open Access

    Divergent Temporal Trends in Site-Specific Sarcoma Mortality in the United States, 1999–2020: A Population-Based Analysis

    by Muhanad Alzahrani, Abdullah Alabbasi, Mohammed Sayes, Rayyan Fahad H Altemani, Ziyad Alzahrani

    Background: Sarcomas are heterogeneous malignancies with prognoses that vary markedly by anatomical site. Whether population-level mortality trends differ across anatomical locations remains unclear. Methods: Sarcoma-related deaths in the United States from 1999 to 2020 were analyzed using the CDC WONDER Underlying Cause of Death database. ICD-10 codes classified deaths into six anatomical categories: bone, retroperitoneal/peritoneal, trunk soft tissue, extremity soft tissue, head and neck, and unspecified. Negative binomial regression models with a population offset estimated site-specific trends, and an interaction model tested heterogeneity across sites. Sensitivity analyses excluded 2020 and recalculated proportions among specified-site deaths only. Results: Nearly half of the deaths were coded to unspecified sites (49.8%), with no improvement over time. Among specified sites, bone accounted for the largest share (22.6%), followed by retroperitoneal/peritoneal sarcomas (15.1%). Overall mortality increased by 1.32% annually (IRR 1.013, 95% CI 1.012–1.014), with significant increases across all specified sites. Decomposition showed that retroperitoneal/peritoneal (43.5%) and bone (29.7%) sarcomas contributed the largest shares of the overall increase. Trend heterogeneity was significant (p < 0.001), with trunk soft-tissue and head-and-neck sarcomas increasing the fastest. Findings were robust after excluding 2020 and in specified-site–only analyses. Conclusions: Mortality coded to sarcoma-related ICD-10 underlying-cause categories increased across all anatomically specified sites, with heterogeneous site-specific trends. Retroperitoneal/peritoneal and bone categories contributed most to the absolute increase, while trunk soft tissue and head and neck categories showed the steepest relative increases.

  • Antibiotic Use at the End of Life: Balancing Symptom Relief, Treatment Burden, and Stewardship

    by Muhanad Alzahrani, Abdullah Alabbasi, Mohammed Sayes, Rayyan Fahad H Altemani, Ziyad Alzahrani

    Background: Antibiotic use remains common among patients receiving palliative and end-of-life care despite limited evidence that treatment consistently improves patient-centered outcomes. Clinicians frequently face uncertainty when balancing potential symptom relief against treatment burden, antimicrobial resistance concerns, and alignment with patient goals of care. Evidence Sources: A structured narrative review was conducted using studies identified through searches of major biomedical databases and reference screening, including observational cohorts, qualitative studies, and reviews addressing antimicrobial use across hospice, hospital, community, and long-term care settings. Findings: Antibiotics are frequently prescribed during the final weeks of life, often without confirmed infection. Symptom benefit varies substantially by infection type; evidence for benefit is strongest for sepsis (approximately 50% response), while urinary tract infections show considerably lower benefit (approximately 17%), and respiratory or source-unclear infections show even less consistent improvement. Treatment burdens include adverse effects, intravenous access discomfort, hospital transfer, and antimicrobial resistance risks. Conclusions: Antibiotic prescribing near the end of life should prioritize patient goals, expected symptom benefit, and minimized treatment burden while incorporating stewardship and shared decision-making strategies.